top of page

Advancing personalised medicine in Europe

BioRN is part of the renowned EU research project PRECISEU


Heidelberg July 8th 

The BioRN Life Science Cluster has a long tradition of researching and developing personalised healthcare. As part of the EU research project PRECISEU, this expertise will now make a significant contribution to accelerating innovations in the field of personalized medicine across Europe.

 

The EU research project PRECISEU, short for "Empowering Personalised Medicine connecting Innovation Regional Ecosystems Across Europe", which was launched in June 2024 with a duration of five years, aims to connect innovation ecosystems across Europe and advance personalised medicine throughout Europe.

BioRN is one of 25 partner organisations from eleven European countries that are working together on the further development of tailored healthcare as part of the research project.

 

BioRN recognised the potential of precision medicine for oncology at an early stage and was one of the winners of the nationwide Leading-Edge Cluster Competition in 2008 under the theme "personalised medicine". BioRN will promote the networking of infrastructure to facilitate access for all users and support early research collaborations between industry and academia. In addition, an annual award will be presented for the best regional practices for the implementation of customised medicine in order to initiate cultural change.

 

Gitte Neubauer, CEO of BioRN Network e.V., explains: "Participation in this consortium fits perfectly with our mission to act as a dynamic and innovative life sciences ecosystem beyond the borders of Germany".

Dr. Julia Schaft, Managing Director of BioRN, says: "With our many years of expertise, we want to make a valuable contribution to this strategically important international project and play a decisive role in shaping the future of healthcare. This is a win-win situation for BioRN, as the region will further expand its leading position in personalised medicine."

 

The PRECISEU project will connect regions in Europe to share best practices and solutions and promote innovation in healthcare, focusing on advanced therapy medicinal products (ATMPs) and health data.

The five-year project is funded with a total of 22.7 million euros, half of which comes from the Horizon Europe initiative. It brings together regional authorities, academic institutions, non-governmental organisations and innovation actors. PRECISEU involves innovators, scientists and entrepreneurs in the participating countries, including Spain, Germany, Italy, Belgium, the Netherlands, Sweden, Greece, Romania, Bulgaria, Lithuania and Ukraine.

 

About BioRN

BioRN is the science and industry innovation cluster in the Rhine-Neckar region around Heidelberg, one of Germany’s strongest biotech and life science hubs. It is a non-profit network fostering health innovations and serving its members by creating a rich translational ecosystem as well as promoting, representing and connecting the regional innovation stakeholders. BioRN has around 150 institutional members, including the top academic and research institutions, ten global pharmaceutical companies, a large range of small and medium-sized enterprises bolstering the life science ecosystem as well as local government organizations and interest groups. BioRN develops strategies and concepts to strengthen innovation and translation and to create startup friendly framework conditions. Being a leading life science cluster in Europe, BioRN aims to attract global investment and talent to the region. BioRN is also founding partner of Biolabs in Heidelberg, a leading shared laboratory space for biotech and life science start-ups, part of the global BioLabs network.



2024-07-04_ Pressrelease_PRECISEU_FL_sf_e
.pdf
Download PDF • 160KB

 

Follow us on Twitter (@BioRNCluster) and LinkedIn. (www.biorn.org)

Media – Contact:

Stephanie Füller

Public Relations Manager

mobile:+49-15117880177E-Mail: sf@biorn.org

BioRN Network e.V.Im Neuenheimer Feld 58469120 Heidelberg, Germany

 

 

 

Comments


bottom of page